Drug Profile


Alternative Names: Androxal; Enclomid; Enclomifene citrate; Enclomiphene; Enclomiphene citrate; trans-clomifene

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Repros Therapeutics
  • Class Antineoplastics; Diethylamines; Ethanolamines; Small molecules; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists; Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Hypogonadism
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 05 Oct 2016 The EMA accepts MAA dossier for enclomifene for Secondary hypogonadism for review
  • 12 Sep 2016 Preregistration for Secondary hypogonadism in European Union (PO)
  • 15 Aug 2016 Interim efficacy data from a phase II trial in Secondary hypogonadism released by Repros Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top